Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor
I. Determine the number of days of apheresis required to reach >= 5 x 10^6 CD34 cells/kg.
II. Determine the total number of CD34 cells/kg collected in a maximum of 4 days if >= 5 x
10^6 CD34 cells/kg is not obtained.
Patients receive rituximab IV on day 1, etoposide IV on days 2-4, and carboplatin and
ifosfamide IV on day 3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once
daily beginning on day 6 and continuing until apheresis is completed and plerixafor SC once
daily for up to 4 days beginning 24 hours after recovery from nadir and continuing until
apheresis is completed. Patients may undergo up to 4 apheresis procedures until the optimal
number of CD34+ cells are collected.
After completion of study treatment, patients are followed periodically for up to 12 months.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Ability to mobilize an adequate number of autologous PBSC
Up to 12 months
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
United States: Institutional Review Board
|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium||Seattle, Washington 98109|